Mauna

Convergent Dental, Inc. Announces Retirement of Founder-CEO

Retrieved on: 
Thursday, June 30, 2022
Patient, CEO, The Advisory Board Company, Medtronic, Adoption, Needle, Northwestern University, Mauna, Bovie Medical, American University, Percussion section, Growth, Solea, Company, Innovation, BSBA, MBA, Retirement, Technology, NYSE, Anesthetic, Dentist, Fear, Board, Management, Dentistry, Covidien, Euronext

NEEDHAM, Mass., June 30, 2022 /PRNewswire-PRWeb/ -- Convergent Dental, Inc. today announced the retirement of Mike Cataldo, founder-CEO. Robert L. Gershon will assume the role of Chief Executive Officer following Mike's retirement on July 18, 2022.

Key Points: 
  • NEEDHAM, Mass., June 30, 2022 /PRNewswire-PRWeb/ -- Convergent Dental, Inc. today announced the retirement of Mike Cataldo, founder-CEO.
  • Robert L. Gershon will assume the role of Chief Executive Officer following Mike's retirement on July 18, 2022.
  • "The company was founded to solve a problem called 'fear of the dentist' by enabling reliably drill-free, needle-free fillings with Solea.
  • Convergent Dental, Inc., headquartered in Needham, Massachusetts, is a privately owned dental equipment and technology company.

Nuvo Group Announces Appointment of Joseph DeVivo to Board of Directors

Retrieved on: 
Wednesday, June 2, 2021
Nuvo, Mauna

"I look forward to combining my personal passion and professional experience to help usher Nuvo and INVU into the company's next chapter."

Key Points: 
  • "I look forward to combining my personal passion and professional experience to help usher Nuvo and INVU into the company's next chapter."
  • With this appointment, DeVivo brings extensive healthcare leadership experience to Nuvo Group.
  • In addition to his role with Nuvo, DeVivo serves on the boards of St. Jude's Children's Research Hospital, Mauna Kea Technologies and AdvaMed, where he chairs the Digital Health Executive Leadership Group.
  • Nuvo Group is committed to serving providers and expectant mothers by advancing pregnancy care with new technology, tools and practices.

Step Into A Vintage Paradise With New Fine Art Photography Series "Gray Malin At The Mauna Kea"

Retrieved on: 
Tuesday, January 26, 2021
Volcanoes, Geological history of Earth, Mauna Kea Beach Hotel, Gray Malin, Volcanism, Mauna Kea, Mauna, Kaunaoa Bay, Hawaii, Malin

WAIMEA, Hawaii, Jan. 26, 2021 /PRNewswire-PRWeb/ --Fine art photographer Gray Malin has partnered with Mauna Kea Beach Hotel to debut his most recent fine art series - Gray Malin at the Mauna Kea.

Key Points: 
  • WAIMEA, Hawaii, Jan. 26, 2021 /PRNewswire-PRWeb/ --Fine art photographer Gray Malin has partnered with Mauna Kea Beach Hotel to debut his most recent fine art series - Gray Malin at the Mauna Kea.
  • Utilizing vintage props, colorful surfboards and striped beachside umbrellas, Gray brings to life carefully crafted moments throughout the resort's most iconic and eye-catching locations.
  • "We are honored to see the timeless beauty of Mauna Kea Beach Hotel come alive in this new photography series from Gray Malin," said Craig Anderson, Vice President of Operations for Mauna Kea Resort.
  • Gray Malin is a modern day fine art photographer, New York Times Bestselling Author and CEO of his namesake brand, Gray Malin.

Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the “Imaging and Robotics in Surgery (IRiS) Alliance”

Retrieved on: 
Tuesday, December 15, 2020
Science, Biotechnology, Research, Surgery, Oncology, Health, Genetics, Clinical trials, Volcanoes, Volcanism, Geological history of Earth, Mauna Kea, Mauna, Kea, Thirty Meter Telescope, Telix Pharmaceuticals Limited, Mauna Kea Technologies

The Telix and Mauna Kea scientific and clinical research collaboration is called the Imaging and Robotics in Surgery (IRiS) Alliance, or IRiS Alliance, and was created to further develop the combined technological capabilities of both companies.

Key Points: 
  • The Telix and Mauna Kea scientific and clinical research collaboration is called the Imaging and Robotics in Surgery (IRiS) Alliance, or IRiS Alliance, and was created to further develop the combined technological capabilities of both companies.
  • We are excited to announce this exclusive scientific and clinical research collaboration with Telix in the field of urologic oncology, said Robert L. Gershon, Chief Executive Officer of Mauna Kea Technologies.
  • Such forward looking statements are based on assumptions that Mauna Kea Technologies considers to be reasonable.
  • The forward-looking statements contained in this release are also subject to risks unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not consider material at this time.

Mauna Kea Technologies Announces Two New Publications Demonstrating the Efficacy, Safety and Accuracy of Cellvizio® for Pancreatic Cyst Evaluation

Retrieved on: 
Wednesday, November 4, 2020
Biotechnology, Genetics, Health, Oncology, Volcanoes, Volcanism, Geological history of Earth, Mauna Kea, Mauna, Dia, Kea, Thirty Meter Telescope

Ten studies enrolling 536 patients were included and the authors evaluated diagnostic accuracy, pooled sensitivity, specificity, and mean procedural time.

Key Points: 
  • Ten studies enrolling 536 patients were included and the authors evaluated diagnostic accuracy, pooled sensitivity, specificity, and mean procedural time.
  • For more information on Mauna Kea Technologies, visit www.maunakeatech.com
    This press release contains forward-looking statements concerning Mauna Kea Technologies and its activities.
  • Such forward looking statements are based on assumptions that Mauna Kea Technologies considers to be reasonable.
  • The forward-looking statements contained in this release are also subject to risks unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not consider material at this time.

Mauna Kea Technologies: Cellvizio® Endorsed By the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) as a Safe and Effective Diagnostic Tool

Retrieved on: 
Tuesday, May 26, 2020
Science, Biotechnology, Research, Pharmaceutical, Surgery, Oncology, Health, Clinical trials, Medicine, Clinical medicine, Medical specialties, Diagnostic gastroenterology, Society of American Gastrointestinal and Endoscopic Surgeons, Endoscopy, Mauna Kea Technologies, Mauna, Bleeding, Gastrointestinal tract disorders

TAVACs objective was to evaluate the safety, value, and efficacy of CLE in the gastrointestinal tract.

Key Points: 
  • TAVACs objective was to evaluate the safety, value, and efficacy of CLE in the gastrointestinal tract.
  • Early diagnosis and effective surveillance can have significant positive impacts on therapeutic management, and Cellvizio is an essential tool to improve diagnostic accuracy and reduce inappropriate interventions.
  • SAGES (The Society of American Gastrointestinal and Endoscopic Surgeons) was founded in 1981 to foster, promote, support and encourage academic, clinical and research achievement in gastrointestinal endoscopic surgery.
  • For more information on Mauna Kea Technologies, visit www.maunakeatech.com
    This press release contains forward-looking statements concerning Mauna Kea Technologies and its activities.

Mauna Kea Technologies Receives FDA Clearance And CE Marking For Its Next-Generation Cellvizio® Platform

Retrieved on: 
Tuesday, March 3, 2020
Science, Radiology, Biotechnology, Research, Pharmaceutical, Health, FDA, Medical devices, Volcanoes, Volcanology, Igneous petrology, Mauna Kea Technologies, Mauna Kea, Mauna, Thirty Meter Telescope

This marks the 18th U.S. FDA 510(k) clearance of the Cellvizio pCLE/nCLE platform.

Key Points: 
  • This marks the 18th U.S. FDA 510(k) clearance of the Cellvizio pCLE/nCLE platform.
  • "We are proud to announce the FDA clearance and CE marking of our next generation Cellvizio in the USA and in Europe," said Robert L. Gershon, Chief Executive Officer of Mauna Kea Technologies.
  • For more information on Mauna Kea Technologies, visit www.maunakeatech.com
    This press release contains forward-looking statements concerning Mauna Kea Technologies and its activities.
  • The forward-looking statements contained in this release are also subject to risks unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not consider material at this time.

Mauna Kea Technologies Receives FDA 510(k) Clearance of Cellvizio® with a Fluorescent Dye, Fluorescein, as Drug Device Combination

Retrieved on: 
Monday, January 27, 2020
Health, FDA, Medical devices, Other Health, Radiology, Pharmaceutical, Biotechnology, Volcanoes, Mauna Kea Technologies, Volcanology, Igneous petrology, Mauna, Food and Drug Administration, Thirty Meter Telescope

Real-world data, published in multiple peer-reviewed medical journals by leading investigators, paved the way for this new FDA clearance.

Key Points: 
  • Real-world data, published in multiple peer-reviewed medical journals by leading investigators, paved the way for this new FDA clearance.
  • This new FDA clearance of our Cellvizio platform in combination with a fluorescent dye is a major regulatory milestone for Mauna Kea Technologies.
  • This clearance is another step for Mauna Kea Technologies in an accelerated development of drug-device combination indications, enabling the clinical use of Cellvizio with highly specific molecular imaging markers.
  • The forward-looking statements contained in this release are also subject to risks unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not consider material at this time.

7-Eleven Canada Brings the Taste of Hawaii to Canadians During the Dreaded Winter Months

Retrieved on: 
Monday, January 20, 2020
Volcanoes, Kona, Mauna Loa, Mauna, Hawaii

7-Eleven Canada is here to cure the post-holiday blues, pulling customers out of their winter slumps.

Key Points: 
  • 7-Eleven Canada is here to cure the post-holiday blues, pulling customers out of their winter slumps.
  • Grown and harvested on the slopes of the Mauna Loa on the Big Island, Kona blend coffee is rich in flavour and fresh from the sun-kissed shores of Hawaii.
  • Every winter, Canadians are invited to indulge in the warm comfort, balanced flavour and smooth finish of 7-Eleven's exclusive Kona Blend, escaping the dreaded Canadian winters, even just for a moment.
  • "With a long winter still ahead, we want to make our customers days a little brighter by bringing that Hawaiian feeling home."

Mauna Kea Technologies Announces Publication of Positive Results on Needle-Based Endomicroscopy for the Clinical Management of Pancreatic Cystic Lesions

Retrieved on: 
Wednesday, January 8, 2020
Biotechnology, Health, Other Health, Pharmaceutical, Surgery, Oncology, Medical devices, Managed care, Infectious diseases, General Health, Hospitals, Genetics, Clinical trials, Medical Supplies, Volcanoes, Mauna Kea Technologies, Endomicroscopy, Volcanology, Igneous petrology, Mauna Kea, Mauna, Thirty Meter Telescope

The article, entitled Impact of EUS-guided microforceps biopsy and needle-based confocal laser endomicroscopy on the diagnostic yield and clinical management of pancreatic cystic lesions was published in Gastrointestinal Endoscopy (2019, DOI: 10.1016/j.gie.2019.12.022 ).

Key Points: 
  • The article, entitled Impact of EUS-guided microforceps biopsy and needle-based confocal laser endomicroscopy on the diagnostic yield and clinical management of pancreatic cystic lesions was published in Gastrointestinal Endoscopy (2019, DOI: 10.1016/j.gie.2019.12.022 ).
  • The management of PCLs using SOC is further challenged by the lack of optimal diagnostics and divergent patient management guidelines.
  • For more information on Mauna Kea Technologies, visit www.maunakeatech.com
    This press release contains forward-looking statements concerning Mauna Kea Technologies and its activities.
  • The forward-looking statements contained in this release are also subject to risks unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not consider material at this time.